An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
|
|
|
Angela Ballantyne, PhD, Moores Cancer Center (MCC), Senior Director of Research Development and Translational Initiatives, was recognized in March 2023 for her 35-year anniversary with UC San Diego Health Sciences! For the past 4-1/2 years, she has worked with the MCC Director and MCC Executive Director for Administration to develop and administrate the entire portfolio of research, training, and education programs at MCC. Thank you Dr. Ballantyne for your expertise, dedication, and contributions at not only MCC, but also UC San Diego Health Sciences.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
| DRM Seminar Series
Decoding Human Hematopoietic Stem Cell Genesis and Self-renewal
Monday, April 24, 2023 from 3:00 p.m. to 4:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
Zoom link available upon request
Hanna Mikkola, MD, PhD
Professor, Molecular, Cell, and Developmental Biology
Eli and Edythe Broad Center of Regenerative Medicine and Stem Cell Research
University of California, Los Angeles
Hosted by Catriona Jamieson, MD, PhD
|
|
|
| Pharmacology Seminar Series
Exploring the Regulatory Apparatus of Bruton’s Tyrosine Kinase: A Drug Target for B-cell Cancers
Tuesday, April 25, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
Amy H. Andreotti, PhD
Roy J. Carver Chair
University Professor of Biochemistry, Biophysics, and Molecular Biology
Iowa State University
Hosted by Alexandra Newton, PhD
|
|
|
| SFG Cross-Lab Meeting: Mesirov Lab
Inter- and Intra-tumoral Heterogeneity of Circular Extrachromosomal DNA in High-risk Medulloblastoma
Wednesday, April 26, 2023 at 12:00 p.m. PT
MCC Comer Commons
Zoom Link
Owen Chapman, BA
Ph.D. Candidate, Mesirov and Chavez Labs
Bioinformatics and Systems Biology (BISB) PhD Program
Department of Biomedical Informatics
UC San Diego, School of Medicine
Sanford Burnham Prebys Medical Discovery Institute
|
|
|
| Pharmacology Seminar Series
Exploring Metabolic Interactions in Tumor Neighborhoods
Tuesday, May 2, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
Zoom Link
M. Celeste Simon, PhD
Scientific Director and Investigator
Abramson Family Cancer Research Institute
Associate Director, Shared Resources
Abramson Cancer Center
Arthur H. Rubenstein, MBBCh Professor
University of Pennsylvania, Perelman School of Medicine
Department of Cell and Developmental Biology
|
|
|
| DRM Seminar Series
Spatial Analysis of RNA Distribution During Early Mammalian Embryogenesis
Monday, May 8, 2023 from 3:00 p.m. to 4:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
Elsy Buitrago Delgado, PhD
Hanna Gray Postdoctoral Fellow
California Institute of Technology
|
|
|
| DRM Seminar Series
Skeletal Muscle in Three Dimensions: Uncovering Connections Across Development
Monday, May 8, 2023 from 4:00 p.m. to 5:00 p.m.
Sanford Consortium for Regenerative Medicine
Conference Room 1013 A/B
Matthew A. Romero, PhD
A.P. Giannini Postdoctoral Fellow
Ford Foundation Postdoctoral Fellow
University of California President’s Postdoctoral Fellow
University of California, Los Angeles
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Better Health through Better Understanding: Cancer Disparities in San Diego
You are invited to attend Better Health Through Better Understanding: Cancer Disparities in San Diego on April 26, 2023 at 12:00 p.m., as part of National Minority and Multicultural Health Month. This webinar is free and open to all those interested. The webinar will target the cancer burden in San Diego County and research addressing cancer disparities.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC Cancer Research, Training, and Education Coordination (CRTEC). These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Call for Letters of Intent: V Foundation 2023 Pediatric Cancer Research Grants: Therapeutic Resistance
Pediatric Translational Cancer Research Grant
Applicants for this RFA may propose pediatric cancer research that moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to develop biomarkers or mechanisms. The research should apply in some direct way to human beings within the time frame of less than 3 years from the end of the grant. If biomarker research is undertaken, then a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.
This RFA is for pediatric cancer research that falls into preclinical/translational research as described above. This year, V Foundation has a special interest in and funding for therapeutic resistance and welcomes research projects in this area. Research areas not covered in this RFA are epidemiology, behavioral science, and health services research.
The grant amount is $800,000, to be dispersed in four annual installments of $200,000.
Before proceeding with an application, please check for applicant eligibility in the RFA, accessible by clicking the blue button below.
Pediatric V Scholar Cancer Research Grant
This RFA will fund pediatric cancer research through the V Scholar grant mechanism and will support young tenure-track faculty early in their cancer research career by funding projects that are either laboratory-based fundamental research or translational research.
This RFA is for pediatric cancer research. This year, V Foundation has a special interest in and funding for therapeutic resistance and welcomes research projects in this area. Research areas not included in this scope are epidemiology, behavioral science, and health services research.
The grant amount is $600,000, to be dispersed in three annual installments of $200,000.
Before proceeding with an application, please check for applicant eligibility in the RFA and V Scholar Decision Tree Handout, accessible via the blue button below.
MCC can nominate only ONE candidate for ONE of these RFAs. To be considered for nomination, please send (1) a 1-page letter of intent and (2) an NIH biosketch to Divya Subramonian, PhD at dsubramonian@health.ucsd.edu for review, which must be submitted as a single PDF by Thursday, May 4, 2023 at 5:00 p.m. Additional instructions are as follows:
|
- Letter of intent / research statement
- Arial font, at least 11-point; at least 1/2-inch margins; 1 page maximum, including any figures, tables, or diagrams; citations may be included only on a second page.
- Include your name, degree(s), title, department, phone number, email address, statement of your eligibility per V Foundation guidelines, and project title.
- Briefly describe the nature of the research project; include a brief summary of aims, significance and rationale, preliminary data, and the research plan.
- NIH-style biosketch
- Five pages maximum; include active and pending support.
-
Your letter of intent submission is NOT complete until you have received an acknowledgment of receipt.
|
Deadline: May 4, 2023 at 5:00 p.m. PT - Open to UC San Diego Faculty Only
|
| |
Alex’s Lemonade Stand Foundation (ALSF), R Accelerated Award Grant
This grant provides funding to scientists who are within their first 10 years of faculty appointment and propose research in pediatric oncology that support ALSF’s mission to find cures and better treatments for childhood cancers. Applicants must present an original project that is not currently funded to accelerate the discovery of more effective, less toxic therapies for childhood cancers. Proposed projects should address a testable hypothesis, based on strong scientific rationale. Applicants must be recipients of an NCI R01 award (or equivalent) addressing pediatric cancer within the last 5 years. Demonstration of not only continued commitment to pediatric cancer research, but also institutional support are essential components of a successful application. The award will total $800,000 over 4 years.
Deadline: May 11, 2023 at 8:00 p.m. ET
|
|
|
Alex’s Lemonade Stand Foundation (ALSF), ‘A’ Award Grant Program
Through the 'A' Award, ALSF seeks game-changing project proposals to substantially advance childhood cancer treatments and cures. The 'A' Award is designed for the early career scientist who wants to establish a career in pediatric oncology research and does not possess independent NIH funding. The ideal candidate will propose an original project and can demonstrate (1) outstanding career development support from his/her institution and (2) strong commitment to future pediatric cancer research. A mentor and a career development plan both are required. The award will total $800,000 over 4 years.
Deadline: May 12, 2023 at 8:00 p.m. ET
|
|
|
Department of Defense (DOD), Ovarian Cancer Research Program (OCRP), Clinical Trial Award (CTA)
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot approximately $6.4M to fund one to three CTA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTA should not exceed $2.0M.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
DOD OCRP Clinical Translational Research Award (CTRA)
The DOD CDMRP will allot approximately $3.2M to fund one to two CTRA applications. The anticipated direct costs budgeted for the entire period of performance for an FY23 OCRP CTRA should not exceed $2.0M.
The DOD CDMRP OCRP CTRA supports correlative studies that are associated with a clinical trial (past, ongoing, or future) to correlate various factors (genetic, biochemical, environmental, and others) with initiation, progression, metastasis, recurrence, prognosis, diagnosis, or effect of intervention on ovarian cancer outcomes. The translational research should address high-impact or unmet needs in ovarian cancer. Although not all-inclusive, research proposed under this mechanism may entail initiation of a deeper molecular analysis of clinical samples, biomarker validation, or continuing clinical follow-up of patients currently/previously enrolled in an open/ongoing or completed clinical trial. The proposed research may be hypothesis testing or may be designed to generate clinically annotated and molecularly characterized experimental platforms (e.g., tissue arrays and patient-derived models). The award may not be used to directly support a clinical trial.
Required Pre-Application Submission Deadline: Friday, May 26, 2023
|
|
|
2023 Bayer-PCF Darolutamide Challenge Awards for Clinical Investigations on Novel Uses of Darolutamide in Prostate Cancer
Award provides up to a total of $1M per team. Approximately $3M is designated for this award mechanism.
PCF and Bayer are pleased to announce a Request for Team Science Applications for Bayer-PCF Challenge Awards to fund novel investigator-initiated clinical investigations that address correlative research for darolutamide in prostate cancer. Proposals will be funded, depending on their level of innovation. PCF and Bayer seek high-risk, currently unfunded projects from only academic institutions in the United States.
Application Submission Deadline: Monday, June 5, 2023 at 3:00 p.m. ET
|
|
|
Society for Immunotherapy of Cancer (SITC), 2023 Regular and Young Investigator Awards
Submit your ground-breaking research for consideration as an oral or poster abstract presentation at SITC 2023, the leading cancer immunotherapy and immunology conference. Regular and Young Investigator Award abstract submissions are being accepted through June 27, 2023 at 5:00 p.m. PT. SITC will offer 38 Young Investigator Awards, which recognize excellence in novel research and provide young investigators with the experience necessary for successful careers. All Young Investigator Award recipients will receive funds to assist with travel expenses for the upcoming 38th Annual SITC Meeting.
Deadline: June 27, 2023 at 5:00 p.m. PT
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
NOSI: Administrative Supplement to Support Global Cancer Stigma Research
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding; applications must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
| DOD Peer Reviewed Cancer Research Program (PRCRP) Impact Award
The DOD Congressionally Directed Medical Research Program (CDMRP) will allot $17.6M to fund approximately 11 PRCRP Impact Award applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP Impact Award should not exceed $1.0M.
Deadline: May 25, 2023
|
| Liver Cancer Collaborative Projects with the Liver Cirrhosis Network (U01 Clinical Trial Optional)
Application budgets may not exceed $250,000 in direct costs; maximum project length is 4 years.
Deadline: June 2, 2023
|
|
|
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: June 15, 2023
|
| Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
| Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
UG3: Application budgets may not exceed $250,000 in direct costs per year; maximum project period is 3 years.
UH3: Application budgets may not exceed $400,000 in direct costs per year; maximum project period is 2 years.
Deadline: June 30, 2023
|
|
|
Addressing the Primary Care Needs of Cancer Survivors (U01 Clinical Trial Required)
Application budgets should reflect the actual needs of the proposed project but must not exceed $700,000 in direct costs per year; maximum project period is 5 years.
Deadline: June 30, 2023
|
| DOD Lung Cancer, Patient-Centered Outcomes and Survivorship Award
The anticipated direct costs budgeted for the entire period of performance for an FY23 LCRP Patient-Centered Outcomes and Survivorship Award should not exceed $650,000.
Deadline: July 20, 2023
|
| DOD Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due date April 17, 2023.
Deadline: July 21, 2023
|
|
|
Understanding Persistent Oral Human Papillomavirus and Human Immunodeficiency Virus Co-infection and Its Role with Oropharyngeal Cancer Induction (R01 Clinical Trial Not Allowed)
Application budgets are not limited; maximum project period is 5 years.
Deadline: July 24, 2023
|
| DOD PRCRP Translational Team Science Award (TTSA)
The DOD CDMRP will allot $36M to fund approximately nine PRCRP TTSA applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP TTSA should not exceed $2.5M.
Deadline: July 25, 2023
|
| DOD PRCRP Patient Well-Being and Survivorship Award (PWSA)
The DOD CDMRP will allot $6.4M to fund approximately four PRCRP PWSA award applications; anticipated direct costs budgeted for the entire period of performance for an FY23 PRCRP PWSA should not exceed $1.0M.
Deadline: July 25, 2023
|
|
|
DOD Lung Cancer Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10, 2023.
Deadline: August 3, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: September 1, 2023
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, and U2C Clinical Trial Optional)
Budgets may not exceed $150,000 in direct costs per year.
Deadline: September 1, 2023
|
|
|
NOSI: Career Development Opportunities for Research Supporting the Mission of the NCI Division of Cancer Prevention (DCP)
This NOSI applies to due dates on or after February 12, 2023 and subsequent receipt dates through November 13, 2024.
|
| NOSI: Technology Development for Cancer Control and Population Science Research
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through December 31, 2024.
|
| NOSI: Research on the Etiology, Early Detection, Screening, and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025.
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
Postdoctoral Positions in Cancer Research
The laboratory of Dr. Thomas Kipps at MCC is seeking highly qualified and motivated postdoctoral fellows (scientists) to participate in state-of-the-art translational cancer research projects to investigate the genetics and immunology of cancer development and the generation of novel pharmacologic cancer therapeutics.
The Kipps laboratory investigates novel therapeutics for patients with leukemia and solid tumors. A particular focus of the laboratory is the function of onco-embryonic antigens, such as ROR1, which are selectively expressed by tumor cells and that contribute to malignant behavior. This involves the development and testing of novel agents that can target such antigens and/or their associated signaling pathways that contribute to the survival, growth, metastatic potential, and/or cancer stemness of neoplastic cells, even in the setting of conventional anti-cancer therapy. These studies can result in the development of more-effective therapies for patients with cancer.
Applicants for these postdoctoral positions must possess a Ph.D., strong analytical skills, proficiency in oral and written scientific presentations, and a demonstrated commitment to a career in cancer research.
These postdoctoral positions are offered preferably to candidates who have recently received their Ph.D. or have completed 3 years or less of post graduate education.
If interested, then submit a cover letter, curriculum vitae, statement of research interests, and the names and contact information of three references to Beth Lipski at elipski@ucsd.edu.
|
|
|
OncLive Institutional Perspectives in Cancer: Gynecologic Cancers
Monday, April 24, 2023 from 6:30 p.m. to 8:00 p.m.
Webinar Only
|
|
|
Perkins Elmer IVIS Facts and Snacks
Tuesday, April 25, 2023 from 10:30 a.m. to 12:30 p.m.
MCC 2nd Floor Breakroom, Room 2325
|
|
|
Donuts with Qiagen and Miltenyi
Wednesday, April 26, 2023 from 2:00 p.m. to 3:00 p.m.
MCC Comer Commons
|
|
|
NanoString Office Hours
Wednesday, April 26, 2023 from 12:45 to 3:15 p.m.
MCC Rasmussen-Wright Conference Room, Room 2250
Discuss GeoMx Digital Spatial Profiler, CosMx Spatial Molecular Imager, and nCounter Analysis System project questions with the NanoString team onsite.
|
|
|
10x Genomics: Single Cell and Spatial Transcriptomic Methods to Understand Cancer
Thursday, April 27, 2023 from 11:00 a.m. to 1:00 p.m.
MCC Comer Commons
Join 10x Genomics representatives to learn how researchers are using their single cell assays and spatial tools to gain a multidimensional view of cancer.
|
|
|
38th Annual Society for Thermal Medicine Meeting
April 23-27, 2023 Catamaran Resort Hotel, San Diego, CA
Visit the Society for Thermal Medicine website for programming, information, and registration.
|
|
|
NCI Virtual Workshop to Engage Multi-Cancer Detection (MCD) Assay Developers
Wednesday, May 3, 2023 from 1:00 p.m. to 5:00 p.m. ET
The NCI Division of Cancer Prevention is hosting a virtual workshop to explain a method of engagement for assay developers who are interested in having their assays considered for selection to the Vanguard study.
This interactive workshop is designed for multi-cancer detection (MCD) assay developers who are interested in participating in trials and studies to be run by a new Cancer Screening Research Network (CSRN) that is being established by NCI, which recognizes the importance of MCD assays and is interested in assessing their use as cancer screening tools. The CSRN is anticipated to start in January 2024, and its initial effort will be launching the Vanguard study (RFA-CA-23-020, RFA-CA-23-021, RFA-CA-23-022).
|
|
|
MCC Structural and Functional Genomics (SFG) Research Program Retreat
Friday, May 5, 2023
MCC Goldberg Auditorium and Lobby
Breakfast and lunch will be provided.
|
|
|
Joseph Califano, MD
Director, MCC
Director, Gleiberman Head and Neck Cancer Center
Professor, Department of Otolaryngology/Head and Neck Surgery UC San Diego, School of Medicine
Co-Leader, MCC, SFG Program
|
| Jill P. Mesirov, PhD
Associate Vice Chancellor for Computational Health Sciences Professor, Department of Medicine
UC San Diego, School of Medicine Co-Leader, MCC, SFG Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University website for updates.
|
|
|
MPN Advocacy and Education International, San Diego Patient and Caregiver Program
Thursday, May 25, 2023 from 9:00 a.m. to 2:00 p.m.
Manchester Grand Hyatt San Diego
1 Market Place San Diego, CA 92101
This program will provide updated information about myeloproliferative neoplasms, available support, treatment options, symptom management, pertinent information regarding stem cell transplants, among other topics. Meet with not only MPN patients and caregivers, but also MPN specialists who will be speaking in the program.
Speakers will include the following experts in the field:
|
- Dr. Catriona Jamieson, UC San Diego
- Dr. James Mangan, UC San Diego
-
Dr. Raajit Rampal, Memorial Sloan Kettering Cancer Center
|
|
|
Newly Opened Clinical Trials
|
|
|
64407564MMY4003: Pre-Approval Access Named Patient Program for Talquetamab (JNJ64407564) for Treating Physician Use in Relapsed or Refractory Multiple Myeloma
PI: Costello, C
NCT: NCT05757973
|
| | |
|
HC366-FCP2111: A Multicenter, Open-label, Phase 1a/b Study of HC7366 in Subjects With Advanced Solid Tumors
PI: Vu, P
NCT: NCT05121948
|
| | |
|
SHARED RESOURCE SPOTLIGHT
|
|
|
MCC Tissue Technology Shared Resource (TTSR) Receives Accreditation from the College of American Pathologists (CAP)
The CAP Accreditation Committee has awarded accreditation to the MCC TTSR, based on results of a recent on-site inspection as part of CAP's Accreditation Programs.
TTSR Director, Alfredo Molinolo, M.D., Ph.D., was advised of this national recognition and congratulated for the excellence of the services being provided. The MCC TTSR lab is one of more than 8,000 CAP-accredited facilities worldwide.
The U.S. federal government recognizes the CAP Laboratory Accreditation Program, begun in the early 1960s, as being equal to or more stringent than the government's own inspection program.
During the CAP accreditation process, which is designed to ensure the highest standards of care for all laboratory patients, inspectors examine a given laboratory's records and quality control of procedures for the preceding 2 years. CAP inspectors also examine laboratory staff qualifications, equipment, facilities, safety program and record, and overall management.
As the world's largest organization of board-certified pathologists and leading provider of laboratory accreditation and proficiency testing programs, CAP serves patients, pathologists, and the public by fostering and advocating excellence in the practice of pathology and laboratory medicine worldwide. For more information, peruse the CAP Annual Report: https://www.cap.org/
|
|
|
-
Yadav S, Boddicker NJ, Na J, Polley EC, Hu C, Hart SN, Gnanaolivu RD, Larson N, Holtegaard S, Huang H, Dunn CA, Teras LR, Patel AV, Lacey JV, Neuhausen SL, Martinez E (CCP), Haiman C, Chen F, Ruddy KJ, Olson JE, John EM, Kurian AW, Sandler DP, O'Brien KM, Taylor JA, et al. Contralateral breast cancer risk among carriers of germline pathogenic variants in ATM, BRCA1, BRCA2, CHEK2, and PALB2. J Clin Oncol. 2023 MAR 20.
- He F, Zhang P, Liu J, Wang R, Kaufman RJ, Yaden BC, Karin M (STT). ATF4 suppresses hepatocarcinogenesis by inducing SLC7A11 (xCT) to block stress-related ferroptosis. J Hepatol. 2023 MAR 28.
-
Chua BA, Lennan CJ, Sunshine MJ, Dreifke D, Chawla A, Bennett EJ, Signer RAJ (HEM). Hematopoietic stem cells preferentially traffic misfolded proteins to aggresomes and depend on aggrephagy to maintain protein homeostasis. Cell Stem Cell. 2023 MAR 16.
-
Tota EM, Devaraj NK (SFG). Site-specific covalent labeling of DNA substrates by an RNA transglycosylase. J Am Chem Soc. 2023 MAR 29.
|
|
|
-
Research Assistant - Cancer Stem Cells - Thomas Kipps, MD Lab - Req #121358
-
Research Assistant - Novel Therapeutics - Stephen Howell, MD Lab - Req #121731
-
Research Associate - Histology - Alfredo Molinolo, PhD Lab - Req #121199
- Biorepository Research Associate - Req #11811
- Research Program Coordinator - Req #119931
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to sjchristie@ucsd.edu. To continue receiving our emails, add us to your address book.
|
|
|
|